Skip to main content
Erschienen in: BMC Endocrine Disorders 1/2020

Open Access 01.12.2020 | Research article

The association of erythrocyte sedimentation rate, high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes

Erschienen in: BMC Endocrine Disorders | Ausgabe 1/2020

Abstract

Background

To evaluate the association between high-sensitivity C-reactive protein (hsCRP) and erythrocyte sedimentation rate (ESR), and diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM).

Methods

A cross-sectional study was conducted in 1210 patients with T2DM, among whom 265 had DKD. The severity of DKD was assessed by estimated-glomerular filtration rate (eGFR) and urinary albumin creatinine ratio (ACR). The relationship between ESR, hsCRP and DKD was analyzed by multivariate logistic analysis. The relationship between ESR and eGFR, ESR or ACR was analyzed by multivariate linear regression.

Results

ESR (23.0 [12.0 ~ 41.5] mm/h versus 12.0 [7.0 ~ 22.0] mm/h, P <  0.001) and hsCRP (3.60 [2.20 ~ 7.65] versus 2.90 [1.80 ~ 5.60] mg/L mg/L, P <  0.01) values were significantly higher in patients with DKD than those without. Patients with higher ESR or hsCRP had lower eGFR and higher ACR. After adjusted for gender, age, hemoglobin, plasma proteins, HbA1c, lipid profiles, and the usage of renin-angiotensin system inhibitors, ESR but not hsCRP was independently associated with the rate and severity of DKD in patients with T2DM.

Conclusion

ESR was independently associated with the rate and severity of DKD in patients with T2DM.
Hinweise
Shizhe Guo and Meng Wang contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
hsCRP
High-sensitivity C-reactive protein
ESR
Erythrocyte sedimentation rate
DKD
Diabetic kidney disease
T2DM
Type 2 diabetes mellitus
eGFR
Estimated-glomerular filtration rate
ACR
Albumin creatinine ratio
ESRD
End-stage renal disease
TNF-α
Tumor necrosis factor-α
IL-8
Interleukin-8
MCP1
Monocyte chemo-attractant protein-1
FBG
Fasting plasma glucose
HbA1c
Glycated hemoglobin
ALB
Albumin
GLB
Globulin
TC
Total cholesterol
TG
Triglyceride
HDL
High-density lipoprotein cholesterol
LDL
Low-density lipoprotein cholesterol
SCr
Serum creatinine
RAS
Renin-angiotensin system
RASi
Renin-angiotensin system inhibitor
WBC
White blood cell
NEU
Neutrophil granulocyte
Hb
Hemoglobin
BMI
Body mass index
OR
Odds ratio
CI
Confidence interval
T
Tertile
SE
Standard error

Background

Type 2 diabetic mellitus (T2DM) is a chronic metabolic disorder with multiple complications, including diabetic retinopathy, diabetic neuropathy, diabetic kidney disease (DKD) as well as cardiovascular diseases [1]. DKD affects 20–40% of patients with T2DM, and is the leading cause of end-stage renal disease (ESRD) [2]. With the rapidly growing prevalence of DKD, there is an overwhelming requirement for biomarkers which can predict the omset and severity of DKD.
T2DM is related to an exacerbated systematic inflammation [3]. Chronic inflammation in patients with T2DM is involved in the onset and development of DKD [4]. Mounting evidences have shown that a number of molecules related to inflammation can be predictable in DKD. Urinary tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), and monocyte chemo-attractant protein-1 (MCP1) are found to be elevated in patients with DKD [5, 6]. Gohda et al. found that circulating TNF receptors were strongly associated with renal function loss in patients with DKD [7]. On ground of this, circulating inflammatory markers might be relevant to the diagnosis and prognosis of DKD [8].
Among all plasma inflammatory biomarkers, erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP) are the mostly commonly used laboratory tests for identifying systematic inflammation [9]. Both ESR and hsCRP are important markers in various inflammation-related diseases. For example, ESR and hsCRP are higher in sarcoidosis patients or osteoarthritis compared to healthy controls [10, 11]. Latest report also revealed that elevated ESR and CRP were associated with the increased urinary albumin excretion [12]. However, there is no study exploring the relationship between ESR, hsCRP and the risk as well as the severity of DKD.
In this study, we retrospectively studied a cohort of 1210 patients with T2DM to investigate the potential relationship between DKD and the degree of systemic inflammation measured by ESR and hsCRP.

Methods

Study design and participants

From January 2013 to October 2017, patients with T2DM who were hospitalized in department of Endocrinology and Metabolism of local hospital were enrolled in this study. The study was approved by the ethics committee of Huashan Hospital (Approval No:2014–250). Written informed consent was obtained from all participants. The exclusion criteria were as follows: (1) patients with immune deficiency; (2) patients with a history of operation or acute coronary syndrome within a month; (3) patients with malignant tumors; (4) patients with a history of inflammatory conditions including current infection, rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, live cirrhosis, tuberculosis, etc.; and (5) patients with the history of steroid usage. All participants included in our study had physical examination and medical history review.

The criteria for diabetic kidney disease

DKD was defined as patients with macro-albuminuria or patients with micro-albuminuria in the presence of diabetic retinopathy according to the diagnostic criteria from KDOQI clinical practice guidelines [13]. Macro-albuminuria was defined as an albumin creatinine ratio (ACR) > 300 mg/g and micro-albuminuria is defined as ACR between 30 and 300 mg/g in two of three urine sample collections [13].

Laboratory parameters

Demographic data (age, gender, status of hypertension) were collected from medical records. Hypertension was diagnosed if patients had history of hypertension or had blood pressure above 140/90 mmHg for twice obtained on ≥2 occasions [14]. Fasting blood sample was collected to measure fasting plasma glucose (FBG), glycated hemoglobin (HbA1c), hsCRP, serum albumin (ALB), globulin (GLB), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), serum creatinine (SCr), and ESR. Besides, the record of renin-angiotensin system (RAS) inhibitors usage was also collected.
The level of HbA1c was measured by liquid chromatography VARIANTTM II and D-10 Systems, BIORAD, USA). ESR was measured using ESR-30 fully automatic dynamic analyzer (Shanghai Xunda Medical Instrument Co., Ltd., China). FBG, TC, TG, HDL, LDL, ALB, total protein, SCr was quantified by Beckman AU5800 (Beckman Coulter Inc., Brea, CA). HsCRP was detected by i-CHROMA reader (Boditech Med inc, Gangwon-do, Korea). Urine was collected for third times and then ACR was immediately measured using Turbidimetry Hitachi system (Roche, Mannheim, Germany). Estimated-glomerular filtration rate (eGFR) was calculated according to CKD-EPI formula (Male: 141 x min (SCr/0.9,1) -0.411 x max (SCr/0.9,1) -1.209 × 0.993 Age; Female: 141 x min (SCr/0.7,1) -0.329 x max (SCr/0.7,1) -1.209 × 0.993 Age× 1.018) [13].

Statistical analysis

All analyses were performed by SPSS version 21.0 for windows system. Categorical variables were exhibited by frequencies and percentages, with X2 test or Fisher’s exact test for detecting the difference. Continuous data was expressed as median values and 25th–75th percentiles because of non-normal distribution analyzed by Kolmogorov-Smirnov test. Kruskal-Wallis test and Mann-Whitney U test were conducted to evaluate the difference. Multivariable linear regression analysis and logistic analysis were used to assess the relationship between inflammatory biomarkers and DKD. A two-tailed P <  0.05 was defined as statistically significant.

Results

Basic characteristics

A total of 1210 patients with T2DM were included in the current analysis, of whom 265 had DKD. Comparison of the characteristics were listed in Table 1. Compared with patients without DKD, patients with DKD showed higher ESR value (12.0 [7.0 ~ 22.0] mm/h vs 23.0 [12.0 ~ 41.5] mm/h, P <  0.001) and higher hsCRP value (2.90 [1.80 ~ 5.60] mg/L vs 3.60 [2.20 ~ 7.65] mg/L, P <  0.01).
Table 1
Characteristics of patients with or without diabetic kidney disease
Variables
Patients without DKD
(n = 945)
Patients with DKD (n = 265)
P value
Age (years)
65.24 (59.00 ~ 75.03)
67.00 (59.70 ~ 79.00)
0.005
Female (n, %)
400 (42.33%)
110 (41.51%)
0.83
Smoking (n, %)
275 (29.1%)
76 (28.7%)
0.90
Duration of T2DM (years)
9.80 (5.35 ~ 14.25)
9.10 (5.50 ~ 14.20)
0.71
BMI (kg/m2)
25.00 (22.25 ~ 27.85)
24.9 (21.90 ~ 28.10)
0.74
Hypertension (%)
598 (63.28%)
221 (83.40%)
<  0.001
Medicine used (n, %)
 Metformin
502 (53.1%)
107 (40.4%)
<  0.001
 Thiazolidinediones
35 (3.7%)
11 (4.2%)
0.74
 Statins
402 (42.5%)
123 (46.4%)
0.26
 Aspirin
236 (25.0%)
85 (32.1%)
0.021
 RASi
365 (40.7%)
151 (57.0%)
<  0.001
ESR (mm/h)
12.00 (7.00 ~ 22.00)
23.00 (12.00 ~ 41.50)
< 0.001
hsCRP (mg/L)
2.90 (1.80 ~ 5.60)
3.60 (2.20 ~ 7.65)
<  0.001
WBC (× 109/L)
6.43 (5.35 ~ 7.76)
6.66 (5.60 ~ 8.01)
0.039
NEU (%)
58.35 (52.03 ~ 64.60)
61.50 (55.45 ~ 68.80)
< 0.001
Hb (g/L)
134.00 (123.00 ~ 146.00)
127.00 (114.00 ~ 136.50)
<  0.001
ALB(g/L)
37.00 (35.00 ~ 40.00)
35.00 (31.00 ~ 38.00)
<  0.001
GLB(g/L)
27.00 (24.00 ~ 30.00)
28.00 (25.00 ~ 31.00)
<  0.001
HbA1c (%)
8.20 (7.00 ~ 9.90)
8.60 (7.30 ~ 10.10)
0.10
FBG (mmol/L)
7.26 (5.82 ~ 9.67)
7.90 (6.10 ~ 10.93)
0.017
TC (mmol/L)
4.26 (3.57 ~ 5.07)
4.46 (3.73 ~ 5.39)
0.006
TG (mmol/L)
1.33 (0.92 ~ 1.97)
1.52 (1.01 ~ 2.22)
0.002
HDL (mmol/L)
0.97 (0.84 ~ 1.15)
0.92 (0.80 ~ 1.08)
< 0.001
LDL (mmol/L)
2.38 (1.82 ~ 3.03)
2.60 (1.83 ~ 3.29)
0.005
ACR (mg/g)
12.56 (7.04 ~ 27.38)
394.49 (96.64 ~ 1316.90)
< 0.001
SCr (μmol/L)
67.84 (56.00 ~ 79.93)
84.00 (64.50 ~ 108.40)
< 0.001
eGFR (ml/min/1.73m2)
92.04 (78.10 ~ 101.72)
75.69 (48.13 ~ 95.18)
< 0.001
Besides, compared with patients without DKD, those with DKD has higher ACR (12.56 [7.04 ~ 27.38] mg/g vs 394.49 [96.64 ~ 1316.90]mg/g, P <  0.001) and lower eGFR (92.04 [78.10 ~ 101.72] ml/min/1.73m2 vs 75.69 [48.13 ~ 95.18] ml/min/1.73m2, P <  0.001), as well as higher GLB, TC, TG, LDL and lower HDL, ALB levels (Table 1). The use of aspirin (p = 0.021) and metformin (p <  0.001) between two groups also reached statistical significance.

Both ESR and hsCRP were associated with renal damage in T2DM

Patients were then divided into three subgroups based on the tertiles of ESR (ESR-T1: ≤8 mm/h, ESR-T2: 8 ~ 21 mm/h, and ESR-T3: > 21 mm/h). The occurrence of DKD rose in accompany with ESR elevation (Fig. 1a, ESR-T1: 11.8%, ESR-T2: 17.0%, and ESR-T3: 35.2%, respectively). Specifically, the difference of incidence between ESR-T1 and ESR-T3 (p <  0.05), and between ESR-T2 and ESR-T3 (p <  0.05), reached statistical significance. Similarly, by dividing patients into three subgroups based on the tertiles of hsCRP (hsCRP-T1: ≤2.3 mg/L, hsCRP-T2: 2.3 ~ 4.5 mg/L, and hsCRP-T3: > 4.5 mg/L), we found that the occurrence of DKD rose when hsCRP elevated (Fig. 1b, hsCRP-T1: 15.8%, hsCRP-T2: 23.6%, and hsCRP-T3: 26.1%, respectively). The difference of incidence between hsCRP-T1 and hsCRP-T2 (p <  0.05), and between hsCRP-T1 and hsCRP-T3 (p <  0.05), reached significance.
Next, we examined the value of eGFR and ACR according to the tertiles of ESR or hsCRP. We found that from ESR-T1 to ESR-T2, and to ESR-T3, eGFR decreased from 95.74 (85.17 ~ 104.37) ml/min/1.73m2 to 89.95 (74.96 ~ 101.12) ml/min/1.73m2, and to 78.61 (54.09 ~ 94.77) ml/min/1.73m2 (Fig. 2a), while ACR increased from 12.42 (6.61 ~ 33.83) mg/g to 16.64 (7.68 ~ 70.54) mg/g, and to 44.08 (12.42 ~ 275.32) mg/g (Fig. 2b). Similarly, from hsCRP-T1 to hsCRP-T2, and to hsCRP-T3, eGFR decreased from 91.94 (78.41 ~ 101.34) ml/min/1.73m2 to 91.17 (75.62 ~ 101.55) ml/min/1.73m2, and to 84.49 (58.48 ~ 98.92) ml/min/1.73m2 (Fig. 2c), while ACR increased from 12.61 (7.33 ~ 40.99) mg/g to 18.61 (7.94 ~ 93.59) mg/g, and to 32.12 (11.80 ~ 155.08) mg/g (Fig. 2d).
Given the different ESR normal range between male and female, gender-based subgroup analysis was conducted. Based on subgroup data, the tertiles for male were ≤ 7 mm/h (mT1), 7 ~ 15 mm/h (mT2), and > 15 mm/h (mT3). Accordingly, eGFR decreased from 95.82 (84.75 ~ 104.31) to 91.41 (78.85 ~ 100.92), and to 79.62 (57.82 ~ 94.56) (Fig. 3a), while ACR increased from 12.84 (6.59 ~ 37.00) to 14.38 (6.59 ~ 70.76), and to 49.56 (12.29 ~ 340.07) (Fig. 3b).
For female, the tertiles were ≤ 14 mm/h (fT1), 14 ~ 26 mm/h (fT2), and > 26 mm/h (fT3). Accordingly, eGFR decreased from 95.24 (82.57 ~ 103.50) to 87.59 (69.89 ~ 100.35) (Fig. 3c), and to 74.52 (46.51 ~ 93.40), while ACR increased from 12.33 (7.36 ~ 28.05) to 22.00 (8.41 ~ 86.10), and to 43.85 (13.35 ~ 345.77) (Fig. 3d).

ESR was independently associated with DKD in T2DM

Logistic analysis showed that the risk of DKD increased with the upregulation of ESR, even after adjustment for age, gender, hypertension, hemoglobin, TC, HDL, ALB, GLB, HbA1c, and the usage of RAS inhibitor. However, hsCRP was not an independent risk factor for DKD after adjustment for confounders (Table 2). Furthermore, based on the adjusted model, ESR was significantly negatively related to eGFR and positively correlated to ACR (Table 3).
Table 2
Relationship between erythrocyte sedimentation rate or high-sensitivity C-reactive protein levels and diabetic kidney disease
Variables
Group
Model 1 OR
(95% CI)
P value
Model 2 OR
(95% CI)
P value
ESR (mm/h)
T1 (< 9)
reference
 
reference
 
T2 (9 ~ 20)
1.52 (1.01 ~ 2.29)
0.04
1.22 (0.78 ~ 1.93)
0.39
T3 (≥20)
4.04 (2.80 ~ 5.84)
< 0.001
2.42 (1.45 ~ 4.03)
< 0.001
hsCRP (mg/L)
T1 (< 2.2)
reference
 
reference
 
T2 (2.2 ~ 4.5)
1.65 (1.15 ~ 2.35)
0.006
1.05 (0.68 ~ 1.61)
0.83
T3 (≥4.5)
1.89 (1.34 ~ 2.67)
< 0.001
1.40 (0.95 ~ 2.08)
0.09
Model 1: unadjusted,
Model 2: adjusted for age, gender, hypertension, hemoglobin, TC, HDL, ALB, GLB, HbA1c, and the usage of RAS inhibitor, metformin, and aspirin
Table 3
Multivariate association of erythrocyte sedimentation rate and severity of diabetic kidney disease
Clinical parameters
ESR
B
SE
beta
P
eGFR
−0.262
0.031
−0.137
< .001
ACR
6.040
1.486
0.155
< .001

Discussion

In this study, we found that patients with DKD had higher ESR and hsCRP levels than those without DKD. Moreover, ESR but not hsCRP was independently related to the risk and severity of DKD, as indicated by both eGFR and ACR.
Growing evidences underline the critical role of inflammation in the progression of DKD. In the early stage of DKD, macrophages accumulate in kidney and produce cell adhesion molecules, chemokines, and pro-inflammatory cytokines [15, 16], which recruit more macrophages into kidney and exacerbate inflammatory injury [17].
Inflammatory parameters such as TNF-α have been reported to be correlated with renal function in T2DM [1822], suggesting the predictive potential of inflammatory marker in this disorder [23]. Numerous factors have been found to be prognostic. For example, Hussain et al. found that galectin-3 and growth differentiation factor-15 were inversely related to eGFR and could be used as a biomarker of renal function [24]. Bian et al. identified serum Activin A as an indicator for the treatment efficacy of DKD [25]. By reviewing the progression of DKD, Cao et al. summarized several microRNAs that could be used as biomarkers and therapeutic targets in DKD [26]. However, the measurement of these factors is expensive, which limits their clinical application. On the other hand, ESR and hsCRP can provide valuable information in terms of inflammatory status in a cheap and convenient manner [27]. They are influenced by various inflammatory factors, making them sensitive to inflammation [28]. In the present study, we found that ESR, instead of hsCRP, was independently associated with the incidence and severity of DKD, indicating the role of ESR for prognosticating DKD onset and progression.
ESR has been in use since 1921 as a test of inflammatory reaction for tuberculosis [27]. As an indicator of inflammation, ESR is widely used as a predictive biomarker in various chronic diseases, including anti-neutrophil cytoplasmic antibody-associated vasculitis [29] and systematic inflammatory response syndrome [30], and can be an independent prognostic factor for osteomyelitis recurrence in patients with T2DM [31]. However, the relationship between ESR and DKD has not been proposed. Based on our findings, ESR elevated significantly in the patients with DKD and is independently associated with DKD. According to our multivariate logistic analysis, patients with higher ESR level were more likely to have concomitant DKD than those with lower ESR. Furthermore, ESR was positively related to the severity of DKD, measured by both renal function and urinary albumin secretion, suggesting the correlation between inflammation and DKD progression. Above all, as a widely-applied and inexpensive measurement, ESR can be an ideal parameter for DKD occurrence and severity in patients with T2DM.
Despite of few literatures on ESR and DKD, the relationship between hsCRP and T2DM or DKD has been widely investigated. In a cross-sectional study including 64 patients with T2DM, hsCRP was significantly higher in those with micro-albuminuria compared to those with normo-albuminuria [32]. Another study reported that hsCRP rose significantly in patients with CKD than those without CKD [33]. However, whether CRP is an independent risk factor for DKD is still controversial. Navarro et al. found that hsCRP was independently associated with albuminuria in T2DM [34]. By contrast, in a study with 467 patients with diabetes and 1014 controls, hsCRP was not independently related to micro-albuminuria [35]. Similarly, a research showed that hsCRP was not independently related to eGFR or urinary albumin secretion, after adjusted for CKD risk factors [33]. Based on our findings with a sample size of 1210, hsCRP was not independently associated with DKD after adjusted confounding factors, although the hsCRP value was significantly higher in patients with DKD than those without DKD.
The current outcomes should still be interpreted with caution. First, this is a cross-sectional study which might have introduced bias. Longitudinal studies are required to define whether ESR could predict the onset of DKD. Besides, ESR was only obtained from a single measurement, which might not be able to reflect a relation over time. However, after taking confounders into consideration, ESR are still associated with measures of DKD.

Conclusion

In conclusion, the current research underlined the role of inflammation in DKD. Our study found that, both ESR and hsCRP correlated with DKD in T2DM, of which ESR was an independent risk factor for DKD and positively associated with severity of DKD.

Acknowledgements

None.
The study was approved by the institutional review board in accordance with the ethical standards established by ethics committee of Huashan Hospital. Written informed consent was obtained from all participants.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.CrossRef Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.CrossRef
2.
Zurück zum Zitat Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864–83.CrossRef Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864–83.CrossRef
3.
Zurück zum Zitat Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, Folkerts G, Friedmann PS, Frost GS, Guarner F, et al. Inflammatory disease processes and interactions with nutrition. Br J Nutr. 2009;101(Suppl 1):S1–45.PubMed Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, Folkerts G, Friedmann PS, Frost GS, Guarner F, et al. Inflammatory disease processes and interactions with nutrition. Br J Nutr. 2009;101(Suppl 1):S1–45.PubMed
4.
Zurück zum Zitat Park DJ, Choi SE, Xu H, Kang JH, Lee KE, Lee JS, Choi YD, Lee SS. Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. Int J Rheum Dis. 2018. Park DJ, Choi SE, Xu H, Kang JH, Lee KE, Lee JS, Choi YD, Lee SS. Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. Int J Rheum Dis. 2018.
5.
Zurück zum Zitat Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C, Koizumi M, Funabiki K, Horikoshi S, Shirato I, et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2002;16(1):1–4.CrossRef Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C, Koizumi M, Funabiki K, Horikoshi S, Shirato I, et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2002;16(1):1–4.CrossRef
6.
Zurück zum Zitat Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, Warram JH, Krolewski AS. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2009;4(1):62–70.CrossRef Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, Warram JH, Krolewski AS. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2009;4(1):62–70.CrossRef
7.
Zurück zum Zitat Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012;23(3):516–24.CrossRef Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012;23(3):516–24.CrossRef
8.
Zurück zum Zitat Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol. 2017;312(4):F716–31.CrossRef Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol. 2017;312(4):F716–31.CrossRef
9.
Zurück zum Zitat Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60(5):1443–50.PubMed Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60(5):1443–50.PubMed
10.
Zurück zum Zitat Mirsaeidi M, Omar HR, Ebrahimi G, Campos M. The association between ESR and CRP and systemic hypertension in Sarcoidosis. Int J Hypertens. 2016;2016:2402515.CrossRef Mirsaeidi M, Omar HR, Ebrahimi G, Campos M. The association between ESR and CRP and systemic hypertension in Sarcoidosis. Int J Hypertens. 2016;2016:2402515.CrossRef
11.
Zurück zum Zitat Wang C, Gong Z, Hu S, Zhang G. Metallothionein-1 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells. Int Immunopharmacol. 2019;75:105815.CrossRef Wang C, Gong Z, Hu S, Zhang G. Metallothionein-1 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells. Int Immunopharmacol. 2019;75:105815.CrossRef
12.
Zurück zum Zitat Ren H, Wu C, Shao Y, Liu S, Zhou Y, Wang Q. Correlation between serum miR-154-5p and urinary albumin excretion rates in patients with type 2 diabetes mellitus: a cross-sectional cohort study. Front Med. 2020. Ren H, Wu C, Shao Y, Liu S, Zhou Y, Wang Q. Correlation between serum miR-154-5p and urinary albumin excretion rates in patients with type 2 diabetes mellitus: a cross-sectional cohort study. Front Med. 2020.
13.
Zurück zum Zitat Kdoqi. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154. Kdoqi. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154.
14.
Zurück zum Zitat Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;2017. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;2017.
15.
Zurück zum Zitat Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65(1):116–28.CrossRef Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65(1):116–28.CrossRef
16.
Zurück zum Zitat Zeng C, Shi X, Zhang B, Liu H, Zhang L, Ding W, Zhao Y. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl). 2012;90(2):175–86.CrossRef Zeng C, Shi X, Zhang B, Liu H, Zhang L, Ding W, Zhao Y. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl). 2012;90(2):175–86.CrossRef
17.
Zurück zum Zitat Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006;69(1):73–80.CrossRef Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006;69(1):73–80.CrossRef
18.
Zurück zum Zitat Afsar B. The relationship between neutrophil lymphocyte ratio with urinary protein and albumin excretion in newly diagnosed patients with type 2 diabetes. Am J Med Sci. 2014;347(3):217–20.CrossRef Afsar B. The relationship between neutrophil lymphocyte ratio with urinary protein and albumin excretion in newly diagnosed patients with type 2 diabetes. Am J Med Sci. 2014;347(3):217–20.CrossRef
19.
Zurück zum Zitat Azab B, Daoud J, Naeem FB, Nasr R, Ross J, Ghimire P, Siddiqui A, Azzi N, Rihana N, Abdallah M, et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients (3-year follow-up study). Ren Fail. 2012;34(5):571–6.CrossRef Azab B, Daoud J, Naeem FB, Nasr R, Ross J, Ghimire P, Siddiqui A, Azzi N, Rihana N, Abdallah M, et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients (3-year follow-up study). Ren Fail. 2012;34(5):571–6.CrossRef
20.
Zurück zum Zitat Huang W, Huang J, Liu Q, Lin F, He Z, Zeng Z, He L. Neutrophil-lymphocyte ratio is a reliable predictive marker for early-stage diabetic nephropathy. Clin Endocrinol. 2015;82(2):229–33.CrossRef Huang W, Huang J, Liu Q, Lin F, He Z, Zeng Z, He L. Neutrophil-lymphocyte ratio is a reliable predictive marker for early-stage diabetic nephropathy. Clin Endocrinol. 2015;82(2):229–33.CrossRef
21.
Zurück zum Zitat Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30(1):49–59.CrossRef Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30(1):49–59.CrossRef
22.
Zurück zum Zitat Navarro JF, Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. TheScientificWorldJournal. 2006;6:908–17.CrossRef Navarro JF, Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. TheScientificWorldJournal. 2006;6:908–17.CrossRef
23.
Zurück zum Zitat Heo JM, Park JH, Kim JH, You SH, Kim JS, Ahn CM, Hong SJ, Shin KH, Lim DS. Comparison of inflammatory markers between diabetic and nondiabetic ST segment elevation myocardial infarction. J Cardiol. 2012;60(3):204–9.CrossRef Heo JM, Park JH, Kim JH, You SH, Kim JS, Ahn CM, Hong SJ, Shin KH, Lim DS. Comparison of inflammatory markers between diabetic and nondiabetic ST segment elevation myocardial infarction. J Cardiol. 2012;60(3):204–9.CrossRef
24.
Zurück zum Zitat Hussain S, Habib A, Hussain MS, Najmi AK. Potential biomarkers for early detection of diabetic kidney disease. Diabetes Res Clin Pract. 2020;161:108082.CrossRef Hussain S, Habib A, Hussain MS, Najmi AK. Potential biomarkers for early detection of diabetic kidney disease. Diabetes Res Clin Pract. 2020;161:108082.CrossRef
25.
Zurück zum Zitat Bian X, Griffin TP, Zhu X, Islam MN, Conley SM, Eirin A, Tang H, O'Shea PM, Palmer AK, McCoy RG, et al. Senescence marker activin a is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy. BMJ Open Diabetes Res Care. 2019;7(1):e000720.CrossRef Bian X, Griffin TP, Zhu X, Islam MN, Conley SM, Eirin A, Tang H, O'Shea PM, Palmer AK, McCoy RG, et al. Senescence marker activin a is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy. BMJ Open Diabetes Res Care. 2019;7(1):e000720.CrossRef
26.
Zurück zum Zitat Cao Q, Chen XM, Huang C, Pollock CA. MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: an update. FASEB Bioadv. 2019;1(6):375–88.PubMedPubMedCentral Cao Q, Chen XM, Huang C, Pollock CA. MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: an update. FASEB Bioadv. 2019;1(6):375–88.PubMedPubMedCentral
27.
Zurück zum Zitat Osei-Bimpong A, Meek JH, Lewis SM. ESR or CRP? A comparison of their clinical utility. Hematology. 2007;12(4):353–7.CrossRef Osei-Bimpong A, Meek JH, Lewis SM. ESR or CRP? A comparison of their clinical utility. Hematology. 2007;12(4):353–7.CrossRef
28.
Zurück zum Zitat Lapić I, Padoan A, Bozzato D, Plebani M. Erythrocyte Sedimentation Rate and C-Reactive Protein in Acute Inflammation. Am J Clin Pathol. 2020;153(1):1–16. Lapić I, Padoan A, Bozzato D, Plebani M. Erythrocyte Sedimentation Rate and C-Reactive Protein in Acute Inflammation. Am J Clin Pathol. 2020;153(1):1–16.
29.
Zurück zum Zitat Liang H, Xin M, Zhao L, Wang L, Sun M, Wang J. Serum creatinine level and ESR values associated to clinical pathology types and prognosis of patients with renal injury caused by ANCA-associated vasculitis. Exp Ther Med. 2017;14(6):6059–63.PubMedPubMedCentral Liang H, Xin M, Zhao L, Wang L, Sun M, Wang J. Serum creatinine level and ESR values associated to clinical pathology types and prognosis of patients with renal injury caused by ANCA-associated vasculitis. Exp Ther Med. 2017;14(6):6059–63.PubMedPubMedCentral
30.
Zurück zum Zitat Ganesan V, Brown RD, Jimenez JA, De S, Monga M. C-reactive protein and erythrocyte sedimentation rate predict systemic inflammatory response syndrome after percutaneous Nephrolithotomy. J Endourol. 2017;31(7):638–44.CrossRef Ganesan V, Brown RD, Jimenez JA, De S, Monga M. C-reactive protein and erythrocyte sedimentation rate predict systemic inflammatory response syndrome after percutaneous Nephrolithotomy. J Endourol. 2017;31(7):638–44.CrossRef
31.
Zurück zum Zitat Lin Z, Vasudevan A, Tambyah PA. Use of erythrocyte sedimentation rate and C-reactive protein to predict osteomyelitis recurrence. J Orthop Surg (Hong Kong). 2016;24(1):77–83.CrossRef Lin Z, Vasudevan A, Tambyah PA. Use of erythrocyte sedimentation rate and C-reactive protein to predict osteomyelitis recurrence. J Orthop Surg (Hong Kong). 2016;24(1):77–83.CrossRef
32.
Zurück zum Zitat Gomes MB, Nogueira VG. Acute-phase proteins and microalbuminuria among patients with type 2 diabetes. Diabetes Res Clin Pract. 2004;66(1):31–9.CrossRef Gomes MB, Nogueira VG. Acute-phase proteins and microalbuminuria among patients with type 2 diabetes. Diabetes Res Clin Pract. 2004;66(1):31–9.CrossRef
33.
Zurück zum Zitat Lee BT, Ahmed FA, Hamm LL, Teran FJ, Chen CS, Liu Y, Shah K, Rifai N, Batuman V, Simon EE, et al. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol. 2015;16:77.CrossRef Lee BT, Ahmed FA, Hamm LL, Teran FJ, Chen CS, Liu Y, Shah K, Rifai N, Batuman V, Simon EE, et al. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol. 2015;16:77.CrossRef
34.
Zurück zum Zitat Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003;42(1):53–61.CrossRef Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003;42(1):53–61.CrossRef
35.
Zurück zum Zitat Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int. 2000;58(4):1703–10.CrossRef Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int. 2000;58(4):1703–10.CrossRef
Metadaten
Titel
The association of erythrocyte sedimentation rate, high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes
Publikationsdatum
01.12.2020
Erschienen in
BMC Endocrine Disorders / Ausgabe 1/2020
Elektronische ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-00584-7

Weitere Artikel der Ausgabe 1/2020

BMC Endocrine Disorders 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.